PLIVA d.o.o. Company Profile

Background

PLIVA d.o.o., established in 1921, is the largest pharmaceutical company in Croatia and a leading entity in Southeast Europe. Headquartered in Zagreb, Croatia, PLIVA specializes in the development, production, and distribution of generic pharmaceutical products, including active pharmaceutical ingredients (APIs). The company's mission is to provide high-quality, affordable medicines to enhance the quality of life for patients. PLIVA's vision is to be a reliable partner to the healthcare system, offering superior therapeutic solutions across various medical fields. As a subsidiary of Teva Pharmaceutical Industries Ltd., PLIVA operates within the global pharmaceutical industry, contributing significantly to the generics sector.

Key Strategic Focus

PLIVA's strategic focus centers on the development and manufacturing of generic and niche pharmaceutical products. The company emphasizes:

Core Objectives: Expanding its portfolio of generic medicines, enhancing research and development capabilities, and increasing market penetration in both existing and new regions.

Areas of Specialization: Generic drugs, active pharmaceutical ingredients, and biopharmaceuticals.

Key Technologies Utilized: Advanced manufacturing technologies, research and development facilities, and compliance with global quality standards.

Primary Markets Targeted: Croatia, Southeast Europe, the United States, and Russia.

Financials and Funding

As of August 2025, PLIVA's annual revenue reached $576 million. The company has a history of strategic acquisitions to bolster its market position:

2002: Acquired Sidmak for $152.9 million.

2006: Acquired by Barr Pharmaceuticals for $2.5 billion.

2008: Barr Pharmaceuticals was acquired by Teva Pharmaceutical Industries, integrating PLIVA into Teva's global operations.

These acquisitions have enabled PLIVA to expand its product offerings and enhance its research and development capabilities.

Pipeline Development

PLIVA's pipeline includes a diverse range of generic medicines and active pharmaceutical ingredients across various therapeutic areas. The company focuses on:

Key Pipeline Candidates: Generic versions of widely used medications, including antibiotics, cardiovascular drugs, and central nervous system agents.

Stages of Development: Products at various stages, from preclinical research to market-ready generics.

Target Conditions: Infectious diseases, hypertension, neurological disorders, and other prevalent health conditions.

Anticipated Milestones: Regulatory approvals, market launches, and expansion into new therapeutic areas.

Technological Platform and Innovation

PLIVA distinguishes itself through:

Proprietary Technologies: Advanced manufacturing processes for APIs and finished dosage forms.

Significant Scientific Methods: In-house research and development, including the discovery of azithromycin, a widely used antibiotic.

AI-Driven Capabilities: Integration of artificial intelligence in research and development to enhance drug discovery and development processes.

Leadership Team

PLIVA's leadership comprises experienced professionals dedicated to the company's mission:

Mihael Furjan: Chief Executive Officer, leading strategic initiatives and overseeing operations.

Damir Uzorinac: Vice President External Affairs, managing external relations and communications.

Branimir Preprotic: Head of Process, overseeing manufacturing processes and operational efficiency.

Karmen Popovic: Head of Chemical R&D, leading research and development in chemical pharmaceuticals.

Competitor Profile

Market Insights and Dynamics

The pharmaceutical industry, particularly the generics sector, is experiencing significant growth due to increasing healthcare demands and the expiration of patents for branded drugs. PLIVA's strategic focus on generics positions it well to capitalize on this trend.

Competitor Analysis

Key competitors in the region include:

Krka: A Slovenian pharmaceutical company known for its generic medicines.

Egis: A Hungarian company specializing in generic pharmaceuticals.

Actavis: An Icelandic generics manufacturer that has shown interest in acquiring PLIVA in the past.

These competitors offer similar products and target overlapping markets, contributing to a competitive landscape.

Strategic Collaborations and Partnerships

PLIVA has established significant collaborations, including:

Pfizer: Licensing agreement for the antibiotic azithromycin, marketed as Zithromax.

Teva Pharmaceutical Industries: Acquisition in 2008, integrating PLIVA into Teva's global operations.

These partnerships have enhanced PLIVA's market reach and product development capabilities.

Operational Insights

PLIVA's strategic considerations include:

Major Competitors: Krka, EGIS, and Actavis.

Market Position: Leading position in Croatia and Southeast Europe, with a strong export focus.

Competitive Advantages: Established brand recognition, extensive product portfolio, and integration with Teva's global network.

Strategic Opportunities and Future Directions

PLIVA's strategic roadmap includes:

Expansion: Entering new markets and therapeutic areas.

Innovation: Enhancing research and development capabilities, including AI integration.

Sustainability: Implementing sustainable and ethical business practices.

These initiatives position PLIVA to achieve future objectives and strengthen its market presence.

pliva